Cancer is able to counter normal immune functions that are deleterious to its progression by disrupting common immune effector cell function through a reduction in FAS (Fas cell surface death, CD95) receptor surface expression, and increased expression of FAS-mediated apoptosis inhibitors [15], or by disrupting cytotoxic immune signalling [16]. The gene discussed is FAS; the disease is cancer.